These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 35317190)

  • 21. Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?
    Jung C; Kmiec D; Koepke L; Zech F; Jacob T; Sparrer KMJ; Kirchhoff F
    J Virol; 2022 Mar; 96(6):e0207721. PubMed ID: 35225672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
    Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
    J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant.
    Tian D; Sun Y; Xu H; Ye Q
    J Med Virol; 2022 Jun; 94(6):2376-2383. PubMed ID: 35118687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein.
    Javanmardi K; Segall-Shapiro TH; Chou CW; Boutz DR; Olsen RJ; Xie X; Xia H; Shi PY; Johnson CD; Annapareddy A; Weaver S; Musser JM; Ellington AD; Finkelstein IJ; Gollihar JD
    Cell Host Microbe; 2022 Sep; 30(9):1242-1254.e6. PubMed ID: 35988543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.
    Abduljaleel Z; Melebari S; Athar M; Dehlawi S; Udhaya Kumar S; Aziz SA; Dannoun AI; Malik SM; Thasleem J; George Priya Doss C
    Cell Signal; 2023 Sep; 109():110798. PubMed ID: 37423342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research.
    Souza Rocha W; Zhan P; Ferreira da Silva-Júnior E
    Curr Top Med Chem; 2023; 23(17):1625-1639. PubMed ID: 37055893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    Kumar S; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Oct; 94(10):4780-4791. PubMed ID: 35680610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions.
    Dhawan M; Sharma A; Priyanka ; Thakur N; Rajkhowa TK; Choudhary OP
    Hum Vaccin Immunother; 2022 Nov; 18(5):2068883. PubMed ID: 35507895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.
    Zhou Y; Zhi H; Teng Y
    J Med Virol; 2023 Jan; 95(1):e28138. PubMed ID: 36097349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Pharmacological Efficacy of COVID-19 Vaccines against the Variants of Concerns (VOCs) of SARS-CoV-2: Recent Clinical Studies on Booster Dose.
    Zhao D; Wang X; Liu J; Au C; Basavaraj V; Sri CD; Nikolenko VN; Beeraka NM; Shivaprakash P; Fan R
    Curr Pharm Biotechnol; 2023; 24(13):1603-1612. PubMed ID: 36843370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research progress in spike mutations of SARS-CoV-2 variants and vaccine development.
    He X; He C; Hong W; Yang J; Wei X
    Med Res Rev; 2023 Jul; 43(4):932-971. PubMed ID: 36929527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity.
    Khatri R; Siddqui G; Sadhu S; Maithil V; Vishwakarma P; Lohiya B; Goswami A; Ahmed S; Awasthi A; Samal S
    Med Microbiol Immunol; 2023 Feb; 212(1):103-122. PubMed ID: 36583790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.